ROS1 Rearrangement

CI-VAR-00005074Explore in graph →CIViC 269

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ROS1 Rearrangement	Crizotinib	Predictive	B	Supports Sensitivity Response	4	rejected	EID1442 Study describes the expansion of a phase 1 study of crizotinib in a 50 patient cohort with advanced NSCLC and exhibiting ROS1 rearrangements. Among the 50 patients 72% exhibited a response (3 complete… (full text at CIViC) PMID 25264305 · Shaw et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.